Asembia 2026 Recap: Focus on Affordability
More than 10,000 attendees visited Las Vegas last week for Asembia’s ASX26 Summit. Along with meeting with clients and hosting the Specialty Pharmacy Patient Choice Awards, MMIT representatives attended many excellent sessions on the state of the industry. In one session after another, patients’ ability to afford and access their medication was front and center. […]
How Manufacturers Can Prepare for Impending Changes in PBM Incentives
This article was originally published in Pharmaceutical Executive on April 6, 2026. Pharmacy benefit managers (PBMs) sit at the center of an increasingly complex web of relationships among manufacturers, health insurers, pharmacies and employers. While they streamline negotiations between employers and pharmaceutical companies, increase price competition and standardize claims, formulary and utilization practices, they’ve recently […]
Market Access in 2026: Predictions on DTC Programs, Biosimilars and GLP-1s
To better understand what 2026 might bring, we asked three MMIT market access experts to share their perspectives on upcoming market shifts. Read on for key insights into the year ahead (and don’t miss the first post in this two-part series.) 1. Patients are increasingly gravitating to direct-to-consumer platforms. What effects do you think these […]
Market Access in 2026: Predictions on Policies, Contracting and AI
To better understand what 2026 might bring, we asked three MMIT market access experts to share their perspectives on upcoming market shifts. Read the first of this two-part series for key insights into the year ahead. 1. What’s the biggest challenge for manufacturers launching new products this year? Steve Callahan, Senior Director, Advisory & Insights: […]
Alternative Funding Programs: Short-Term Savings, Long-Term Consequences
The use of alternative funding programs (AFP) has been on the rise in recent years, in keeping with the growing number of self-funded employer health plans. Run by for-profit vendors, AFPs are a relatively new type of specialty carve-out program meant to save employers money by removing certain high-cost medications from their formularies. Instead of […]
The R&D Implications of Market Access Complexity
Our latest research at Norstella strongly suggests that a highly dynamic market access situation in the U.S. is feeding back into upstream decisions around R&D strategy. We explored this topic in detail in a recent white paper, Working Backwards: Patient Access Strategy Is Now Guiding R&D. This article briefly summarizes the first half of the […]
GenAI and RWD in Pharma: 4 Questions to Fuel Effective Insights
This article was originally published in BioPharma Dive. Generative AI (GenAI) has become one of the most talked-about innovations in healthcare analytics, but for life sciences organizations, simply deploying an AI-powered solution is not enough. To truly unlock the power of real-world data (RWD), GenAI must go beyond checking a box or riding the latest […]
How PBMs Are Reshaping Biosimilar Market Access
As biosimilars continue to redefine the specialty drug landscape, payers and their associated pharmacy benefit managers (PBMs) are executing new strategies to capture a larger share of revenue. PBMs are partnering with manufacturers to co-develop and commercialize their own private-labeled biosimilar products. This coordinated approach provides value to both parties, as it enables them to […]
Apples to Apples: Stelara Biosimilars and the Fight for Market Share
Over the next five years, 88 biologics—including several blockbuster agents like Eliquis, Keytruda, Opdivo, and Darzalex—are facing a loss of exclusivity, representing an estimated market of more than $100 billion. After the fierce competition between Humira (adalimumab) biosimilars, manufacturers are keeping a close eye on adoption dynamics for biosimilars of Johnson & Johnson’s autoimmune drug, […]
Quantifying Value: Innovative Contracting for High-Cost Drugs
As high-cost specialty treatments become more common, manufacturers are turning to innovative contracting to boost coverage for their products. Many cell and gene therapies, orphan drugs, and oncology therapies are prohibitively expensive, with costs ranging from several hundred thousand to millions of dollars. Warranty-based agreements help mitigate the risk of paying for these therapies, as […]